X

Drug Profile

K 134

Alternative Names: K-134; OPC-33509

Latest Information Update: 19 Aug 2015

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator D. Western Therapeutics Institute
Developer Kowa
Class Antiplatelets; Antithrombotics; Organic chemicals; Quinolines; Small molecules; Urea compounds
Mechanism of Action Type 3 cyclic nucleotide phosphodiesterase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II Arteriosclerosis obliterans

Most Recent Events

19 Aug 2015 Phase-II development is ongoing in USA and Japan
27 Aug 2014 The primary endpoint was not met in a phase IIb trial for Arteriosclerosis obliterans in Japan
16 Nov 2011 Phase II development is ongoing in USA & Japan

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com